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Regional citrate anticoagulation in continuous venovenous he- Continuous renal replacement therapy (CRRT) has,
mofiltration in critically ill patients with a high risk of bleeding. in recent years, been increasingly employed for the man-
Background. Systemic heparinization is associated with a agement of acute renal failure in critically ill patientshigh rate of bleeding when used to maintain patency of the
[1–6]. Although improvement in survival rates comparedextracorporeal circuit during continuous renal replacement
with intermittent hemodialysis (IHD) has not beentherapy (CRRT) in critically ill patients. Regional anticoagula-
tion can be achieved with citrate, but previously described proven, CRRT is frequently chosen for patients who do
techniques are cumbersome and associated with metabolic not tolerate IHD because of hemodynamic instability.
complications. Pump-assisted venovenous techniques such as continu-
Methods. We designed a simplified system for delivering
ous venovenous hemofiltration (CVVH) are now pre-regional citrate anticoagulation during continuous venovenous
ferred over arteriovenous techniques because of signifi-hemofiltration (CVVH). We evaluated filter life and hemor-
rhagic complications in the first 17 consecutive patients who cantly greater solute clearances and lower rates of
received this therapy at our institution. Blood flow rate was vascular complications [7–9].
set at 180 ml/min. Ultrafiltration rate was maintained at 2.0 One of the main disadvantages with CRRT is the re-
liters/hr and citrate-based replacement fluid (trisodium citrate quirement for anticoagulation in order to prevent clot-13.3 mm, sodium chloride 100 mm, magnesium chloride 0.75
ting of the extracorporeal circuit. Heparin has been themm, dextrose 0.2%) was infused proximal to the filter to main-
most frequently used anticoagulant, but is associatedtain the desired fluid balance. Calcium gluconate was infused
through a separate line to maintain a serum-ionized calcium with a risk of life-threatening hemorrhagic complications
level of 1.0 to 1.1 mm. as high as 25 to 30% [3, 10, 11]. In addition, heparin-
Results. All patients were critically ill and required mechani- induced thrombocytopenia may preclude the use of hep-
cal ventilation and vasopressor therapy. Systemic heparin anti-
arin in some cases (abstract; Chong and Jacques, Inten-coagulation was judged to be contraindicated in all of the
sive Care Med 16:437, 1990) [13]. Although the use ofpatients. A total of 85 filters were used, of which 64 were lost
because of clotting, with a mean life span of 29.5 6 17.9 hours. frequent saline flushes without the use of anticoagulant
The remaining 21 filters were discontinued for other reasons. has been reported by Paganini to increase the duration of
Control of fluid and electrolyte balance and azotemia was excel- the CRRT circuit patency [14], others have experienced
lent (mean serum creatinine after 48 to 72 hr of treatment was frequent clotting of filters with this technique [3, 11].2.4 6 1.2 mg/dl). No bleeding episodes occurred. Two patients,
Various alternative methods have been developed toone with septic shock and the other with fulminant hepatic
confer anticoagulation of the extracorporeal circuit withfailure, developed evidence for citrate toxicity without a signifi-
cant alteration in clinical status. Nine patients survived (52.9%). reduced risk of bleeding, including regional hepariniza-
Conclusion. Our simplified technique of regional anticoagu- tion [15], low molecular weight heparin [16], prostacyclin
lation with citrate is an effective and safe form of anticoagula- [17], and the serine proteinase inhibitor nafamostat [18],
tion for CVVH in critically ill patients with a high risk of but these approaches have not been widely acceptedbleeding.
because of their limitations.
The use of citrate as anticoagulant in hemodialysis (HD)
was first described by Morita et al in 1961 [19], and aKey words: CVVH, continuous renal replacement therapy, hepariniza-
tion, blood flow, anticoagulation, clotting. report by Pinnick et al in 1988 confirmed its usefulness
[20]. In recent years, several reports have demonstratedReceived for publication August 13, 1998
the effectiveness of regional citrate anticoagulation inand in revised form October 29, 1998
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(CAVHDF), and continuous venovenous hemodiafil- Citrate continuous venovenous hemofiltration system
tration (CVVHDF) (abstracts; Falkenhain et al, J Am A diagram of our system of regional citrate anticoagu-
Soc Nephrol 4:344, 1993; Mehta et al, J Am Soc Nephrol lation with CVVH is shown in Figure 1A. The previously
4:368, 1993) [10, 11]. Citrate causes anticoagulation by reported design of regional citrate anticoagulation with
chelation of ionized calcium in the extracorporeal circuit. CAVHD by Mehta et al is illustrated in Figure 1B for
However, systemic anticoagulation does not occur as the comparison [10].
ionized calcium level is restored when blood returning Vascular access was established by insertion of a dou-
from the extracorporeal circuit mixes with venous blood. ble-lumen 14 F catheter (Quinton Instruments, Seattle,
Rapid metabolism of citrate to bicarbonate releases the WA, USA) into either the femoral, subclavian, or internal
calcium and maintains serum bicarbonate. However, pa- jugular vein. We used a Baxter BM 11 CVVH blood pump
tients with severe liver failure and lactic acidosis may (Baxter Healthcare Corporation, Deerfield, IL, USA)
have difficulties metabolizing citrate, which can accumu- and Renaflo II HF700 polysulfone hemofilters (Renal Sys-
late and cause toxicity [21]. tems, Minneapolis, MN, USA). The filters were primed
Although citrate anticoagulation has been shown to with two liters of isotonic saline containing 10,000 U/liter
be effective and safe in CRRT, previously described of heparin. In patients with heparin-induced thrombocyto-
systems are cumbersome and have been associated with penia, priming was performed without heparin. Blood
metabolic complications [10, 11]. It has been widely flow rate was maintained at 180 ml/min as measured
claimed that citrate cannot be used safely with hemofil- after dilution with the replacement fluid. A Travenol 6300
tration alone (CVVH) because of insufficient clearance volumetric infusion pump (Baxter Healthcare) was set
of sodium citrate from the blood, resulting in derange- to maintain a constant ultrafiltration rate at 2 liter/hr.
ments of serum sodium and bicarbonate concentrations. The ultrafiltrate was measured hourly and replaced by
It has been felt that dialysis (diffusive clearance) is neces- continuous infusion with a citrate-based replacement
sary for adequate removal of citrate, as well as the so- fluid to maintain the desired fluid balance. The replace-
dium load caused by the hypertonic trisodium citrate [4, ment fluid contained trisodium citrate 13.3 mmol/liter (40
11, 22, 23]. However, we have designed a simple and
mEq/liter), sodium chloride 100 mmol/liter, magnesium
safe system for delivering regional citrate anticoagula-
chloride 0.75 mmol/liter (1.5 mEq/liter), and 0.2% dex-tion during CVVH. To investigate the efficacy and safety
trose (Table 1). The replacement fluid was infused proxi-of our technique, we evaluated extracorporeal circuit
mal to the filter at a rate dependent on the volume ofpatency and hemorrhagic complications in the first 17
other parenteral solutions administered and the net fluidconsecutive patients with renal failure and a high risk of
removed. Filters were flushed every four hours with 200bleeding who received this form of therapy in the inten-
ml of 0.9% saline. Filters were changed for suspectedsive care units (ICUs) at our institution. We found our
clotting if the ultrafiltration rate decreased to approxi-technique of regional citrate anticoagulation to be sim-
mately 1500 ml/hr for more than two consecutive hours.ple, effective, and safe in this high-risk population.
The serum-ionized calcium level was checked prior to
initiation of CVVH, and if necessary, calcium gluconate
METHODS was infused until the ionized calcium was greater than 1.0
mmol/liter. During CVVH, calcium was infused through aPatients
separate line at a rate determined by a sliding scale.We retrospectively studied the first 17 adult patients
Twenty grams of calcium gluconate in one liter of D5Wwith renal failure who were treated with a new method
was infused at 70 ml/hr for an ionized calcium of 0.9 toof regional citrate anticoagulation with CVVH in the
1.0 mmol/liter, 60 ml/hr for an ionized calcium of 1.0 toICUs at the Massachusetts General Hospital from Au-
1.1 mmol/liter, and 50 ml/hr for an ionized calcium ofgust 1995 through May 1996. The modality of renal re-
1.1 to 1.3 mmol/liter. The median rate of calcium infusionplacement therapy (RRT) was selected by the attending
was 60 ml/hr, which provided 2.8 mmol/hr (5.6 mEq/ hr).nephrologist. In addition to CVVH, many patients also
Three patients received an equivalent sliding scale usingreceived IHD at other times during their hospitalization.
calcium chloride instead of calcium gluconate. PotassiumFourteen patients also received heparin anticoagulation
and magnesium were supplemented as needed.with RRT (including IHD) at other times during their
ICU course. Medical records were reviewed to obtain
Monitoring of therapyinformation on demographic factors, diagnosis, etiology
Serum electrolytes and arterial blood gases were moni-of renal failure, APACHE II illness severity score [24] at
tored every 6 to 12 hours or more frequently if needed.the time of ICU admission, contraindication to heparin,
Serum-ionized calcium was measured every six hours orhemofilter life span, metabolic and coagulation parame-
more often if indicated, and serum total calcium wasters, hemorrhagic episodes, other complications of
CVVH, and survival. measured daily. The nephrology coverage was notified
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Fig. 1. Comparison of our citrate-CVVH sys-
tem (A) and the citrate-CAVHD system of
Mehta et al (B). This was taken from Ravindra
L. Mehta, Brian R. McDonald, May M.
Aguilar, and David M. Ward: Regional citrate
anticoagulation for continuous arteriovenous
hemodialysis in critically ill patients. Kidney
Int 38:976–981, 1990 (used with permission).
Table 1. Composition of citrate replacement fluid Statistics
Trisodium citrate 13.3 mmol/liter Data are reported as a mean and standard devia-




for an ionized calcium below 0.9 or greater than 1.3 The clinical characteristics of the 17 patients are shown
mmol/liter. A complete blood count, coagulation param- in Table 2. There were 7 male and 10 female patients.
eters, phosphate, blood urea nitrogen, and creatinine The mean age was 58.2 6 19.5 (6 sd) years. Twelve of
were monitored at least daily. Activated clotting times the 17 patients were postoperative. Eleven had cardiac or
(ACTs) were not monitored routinely. We did not mea- major vascular surgery, and one underwent a Whipple’s
sure solute clearance rates during this study. However, procedure. All 17 patients had circulatory failure with
prior to this study, we determined the urea and creatinine vasopressor dependency. All of the patients also re-
clearances provided by our CVVH technique. Clear- quired mechanical ventilation. The mean APACHE II
ances were calculated by dividing the ultrafiltrate con- score at the time of ICU admission was 25.6 6 7.5 (N 5
centration by the serum concentration and multiplying 16). Fourteen patients had acute renal failure, and all
were severely oliguric or anuric. One of these 14 patientsby the ultrafiltration rate. Urea clearance was between
25 and 28 ml/min, and creatinine clearance was between had acute renal failure in a functioning renal allograft
with a baseline serum creatinine of 1.3 mg/dl. Three19 and 23 ml/min (data not shown).
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Table 2. Clinical features of the 17 patients treated with citrate-CVVH
APACHE II Contraindication Duration of
Patient Age/sex Diagnosis score to heparin citrate-CVVH Outcome
1 57/M Hepatic failure, hepatorenal syndrome 42 Intraperitoneal hemorrhage ,1 day D
2 84/F AVR, CABG 23 Mediastinal hemorrhage 3 days S
3 62/F Endocarditis and septic shock 24 Acute GI hemorrhage (on 26 days D
heparin)
4 73/F Thoracoabdominal aortic aneurysm 30 Postoperative 4 days D
resection, sepsis
5 38/F Ebstein’s anomaly, cardiac transplanta- 12 Recurrent mediastinal hemor- 9 days S
tion rhage
6 74/F MVR, CABG 18 Mediastinal hemorrhage, throm- 4 days S
bocytopenia
7 69/F Splenorenal bypass with subsequent 28 Thrombocytopenia 4 days S
thrombectomy and redo anastomosis,
sepsis
8 21/M Disseminated meningococcemia, DIC 20 Bleeding from surgical wounds 6 days S
(on heparin), thrombocyto-
penia, coagulopathy
9 79/M Lower extremity bypass graft 31 GI hemorrhage 3 days D
10 38/F Aortic root replacement for abscess, 18 Thrombocytopenia 4 days S
CRF
11 70/M AVR, sepsis, CRF 27 Thrombocytopenia 5 days S
12 66/M Whipple procedure, candida sepsis, 28 Postoperative 24 days D
CRF
13 45/F ASD repair, CABG, hepatic failure 29 Mediastinal hemorrhage 5 days D
14 71/F Ascending aortic aneurysm resection 21 Mediastinal hemorrhage 6 days S
15 34/F Endocarditis, septic pulmonary emboli, 37 Thrombocytopenia, coagulopathy Data missing D
hepatic failure, DIC
16 77/M MVR, CABG 21 Mediastinal hemorrhage, throm- 10 days D
bocytopenia, coagulopathy
17 32/M Hemorrhagic pancreatitis Data missing Hemorrhagic pancreatitis 13 days S
APACHE II scores are at the time of admission to ICU (many were higher at the time of initiation of CVVH). Patients 10, 11, and 12 were on chronic dialysis.
All other patients had acute renal failure. Most patients also received additional forms of RRT at other times during their ICU course. Abbreviations are: M, male;
F, female; AVR, aortic valve replacement; MVR, mitral valve replacement; ASD, atrial septal defect; CABG, coronary artery bypass grafting; DIC, disseminated
intravascular coagulation; CRF, chronic renal failure; GI, gastrointestinal; D, died; S, survived.
patients (10, 11, and 12) had chronic renal failure and 143.1 6 136.3 hours. Sixty-four filters (75.3%) were lost
because of clotting at a mean filter life of 29.5 6 17.9were on maintenance dialysis. Fluid overload was the
most common indication for initiating RRT. In all cases, hours. The rate of citrate replacement fluid infusion var-
ied hourly, depending on the volume of other parenteralCVVH was chosen as the RRT modality because of
solutions administered, the net fluid removed, and thehemodynamic instability. Heparin anticoagulation was
achieved rate of ultrafiltration. The average infusion ratejudged to be contraindicated because of ongoing or re-
of citrate replacement fluid was 1.4 liters per hour, whichcent hemorrhage in 11 patients, severe thrombocyto-
is equivalent to 18.6 mmol/hr of citrate. This provides 2.0penia and/or coagulopathy in 4 patients, and recent ma-
mmol of citrate per liter of blood in the extracorporealjor surgery in 2 patients. Four patients had developed
circuit. We did not find an increase in clotting associatedsevere complications during RRT with heparin anticoag-
with hours of relatively low rates of citrate infusion dueulation and were switched from heparin to citrate antico-
to high rates of infusions of other solutions. If the lowagulation. Three of these patients had suffered life-
rate of citrate infusion was due to a low rate of achievedthreatening bleeding episodes, and one had developed
ultrafiltration, then clotting was usually imminent. Theheparin-induced thrombocytopenia. Five patients briefly
use of 21 filters was discontinued for other reasons thanreceived CVVH with saline flushes without anticoagu-
clotting (catheter problems, performance of diagnosticlant therapy but were converted to citrate anticoagula-
tests or surgical procedures, discontinuation of RRT, ortion because of frequent clotting.
patient’s death).
Efficacy Control of fluid and electrolyte balance and azotemia
was excellent in all 17 patients (Table 3). The meanData on filter life were available for 85 filters from 15
patients. Two patients were excluded from this part of serum creatinine after 48 to 72 hours of treatment was
2.4 mg/dl 6 1.2 (N 5 16) despite severe oliguria or anuriathe analysis because of inadequate information in their
medical records. The total duration of citrate CVVH in all patients. Acid-base balance was well controlled
except for two episodes of worsening metabolic acidosistherapy was 2374 hours, and the mean duration was
Palsson and Niles: Citrate anticoagulation in CVVH 1995
Table 3. Control of azotemia in 16 of the 17 patients be employed safely in patients at high risk of bleeding.
Compared with the previously described technique byVariable N Onset 48–72 hr
Mehta et al, our approach carries significantly less com-BUN 16 67.5638.4 36.3 618.0
Creatinine 16 4.762.7 2.4 61.2 plexity, does not require the use of dialysate, and is
associated with a lower complication rate [10, 11].
Our technique of citrate anticoagulation resulted in a
mean filter life of 29.5 hours, which is comparable to
what has been reported for heparin anticoagulation [25].in patients with septic shock and severe hepatic failure,
Our hemofilter patency rates are similar to those re-respectively (discussed later here).
ported by Falkenhain et al, who employed low-dose ci-
Complications trate with CAVHD (abstract; Falkenhain et al, J Am
Soc Nephrol 4:344, 1993). Mehta et al have reported aNo patient suffered bleeding during CVVH with ci-
mean filter life of 44 hours with their technique of re-trate anticoagulation, despite the high-risk population
gional citrate anticoagulation in CVVHDF (abstract;studied. Prothrombin time (PT) and activated partial
Mehta et al, J Am Soc Nephrol 4:368, 1993). Althoughthromboplastin time (aPTT) were measured routinely,
previous studies have shown a correlation between ACTand in no case were these prolonged by the treatment.
and filter survival [26], we elected not to monitor ACTTwo patients developed citrate toxicity manifested by
in order to keep the complexity as low as possible. Likelow serum-ionized calcium levels (with an elevated se-
several other investigators [3, 11], we had poor experi-rum total calcium level in one), together with exacerba-
ence with frequent saline flushes, without anticoagula-tion of metabolic acidosis with a high serum anion gap.
tion.Patient 8 had septic shock caused by meningococcemia,
An adequate concentration of citrate in the extracor-and patient 13 had fulminant hepatic failure and candida
poreal circuit is necessary to chelate calcium in sufficientsepsis. Serum-ionized calcium levels fell to 0.7 and 0.8
amounts to prevent clotting. We administered citrate-mmol/liter, respectively, and did not correct despite in-
based replacement fluid containing 13.3 mmol/liter oftravenous infusion of large doses of calcium (18 and 81
trisodium citrate at an average rate of 1.4 liter/hr. ThemEq over 12 hr, respectively) in addition to the calcium
net rate of citrate administration was, therefore, 18.6infusion determined by the sliding scale. Neither patient
mmol/hr. A blood flow rate of 180 ml/min measuredhad a significant change in clinical status attributable to
after the infusion of the replacement fluid produces athe hypocalcemia. In both cases, the replacement fluid
citrate concentration in the extracorporeal circuit of 2.0was changed to a fluid containing bicarbonate instead of
mmol/liter of blood. Mehta et al used 4% trisodiumcitrate, and CVVH was carried out in the absence of
citrate (140 mmol/liter), which was infused at an initialanticoagulant. Both patients had improvement of the
rate of 170 ml/hr (range 110 to 210 ml/hr), resultingionized calcium level and the high anion gap metabolic
in 24 mmol/hr (range 18.0 to 28.2 mmol/hr) of citrateacidosis after discontinuation of the citrate anticoagula-
administered. The blood flow rate is not specified in theirtion. All other patients had stable serum calcium levels.
reports, but citrate was administered at 3 to 8% of bloodNo other significant complications occurred during the
flow, giving a predicted range of citrate concentrationtreatment. No patient developed metabolic alkalosis or
of approximately 4.2 to 11.2 mmol/liter of extracorporealhypernatremia.
blood. Thus, when compared with our system, Mehta’s
Outcome technique involves a greater amount of citrate adminis-
tered per liter of blood, which results in longer durationsThe outcome for each patient is shown in Table 2.
of hemofilter patency. However, similar levels of bloodNine of the 17 patients (53%) survived to be discharged
citrate concentration can be achieved with our systemfrom the hospital. Among the survivors, six out of seven
by reducing the blood flow to rates similar to those usedpatients with acute renal failure recovered their renal
by Mehta et al or by increasing the rates of ultrafiltrationfunction, but one patient continued to require dialysis.
and replacement fluid administration. We have recentlyMost of the patients who died had supportive measures
been using a blood flow rate of 120 ml/min (measuredwithdrawn because of persistent multiorgan failure. The
after replacement fluid infusion), which should providemean APACHE II score at the time of ICU admission
further prolongation of filter life without appreciablewas 20.9 6 5.2 for survivors (N 5 8) and 30.2 6 6.7 for
effect on the solute clearance rates.those who died (N 5 8).
We have used a fixed rate of ultrafiltration and varied
the rate of replacement fluid administration to maintain
DISCUSSION fluid balance. This approach leads to variation in the
The results show that our design of regional citrate ratio of citrate to blood on an hourly basis. Although
we did not observe an increase in clotting during hoursanticoagulation for use with CVVH is effective and can
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of relatively low rates of citrate replacement fluid infu- failure and sepsis. Inadequate metabolism of citrate to
sion, it is possible that these hours contributed to partial bicarbonate presumably led to accumulation of citrate
clotting, which, in turn, may have led to a shorter filter and resulted in systemic chelation of calcium, manifested
life. An alternative approach would be to set a fixed rate by low levels of serum-ionized calcium in both patients
of citrate replacement fluid infusion that would provide with a high serum total calcium level in one. There was
more consistent regional anticoagulation. Fluid balance an exacerbation of the high anion gap metabolic acidosis
could then be maintained by adjusting the ultrafiltration in these patients, probably because bicarbonate produc-
rate as desired. Currently, we are unable to use this tion from citrate metabolism did not keep up with the
design because of limitations of our ability to control loss of bicarbonate through the filter [21]. These findings
the ultrafiltration rate by the equipment we are currently were recognized early in both patients, and they were
employing. switched to a replacement solution containing bicarbon-
In the system described by Mehta et al, the infusion ate before there was any alteration in their clinical status.
of concentrated sodium citrate must be counterbalanced Although citrate toxicity is rare, patients must be moni-
by using an appropriate amount of hypotonic, bicarbon- tored closely for this potential complication. We cur-
ate free dialysate. Alkali and sodium balances are depen- rently check ionized calcium levels every four hours at
dent on dialysis efficiency, which may be inconsistent. the beginning of therapy. Subsequently, the frequency
They have reported a high rate of metabolic alkalosis of monitoring ionized calcium can be individualized
(25 to 38%) requiring treatment with hydrochloric acid based on the status of the patient.
[10, 11]. In contrast, we infuse an isotonic solution with The 53% survival rate in our group of patients is at
a citrate concentration set to be similar to the concentra- least comparable to what generally has been achieved
tion of alkali in standard dialysis solutions (40 mEq/ in critically ill patients with acute renal failure [29, 30].
liter). There is no apparent risk of metabolic alkalosis This is intriguing in view of the fact that all the patients
or hypernatremia associated with our system, and we did were severely ill, as is illustrated by the high ICU admis-
not observe these complications in any of our patients. sion APACHE II scores. Furthermore, many of the pa-
However, our system requires a high infusion rate of tients deteriorated appreciably from the time of ICU
replacement fluid in order to administer sufficient citrate admission to the time of initiation of CVVH. However,
for anticoagulation. This demands a high rate of ultrafil- the survival of our patients is not directly comparable
tration for maintenance of fluid balance. Therefore, a to previous studies of acute renal failure in critically ill
filter with a high ultrafiltration coefficient must be used. patients, as our study includes patients with chronic renal
This high rate of ultrafiltration also results in the high failure. Finally, our study lacks a control group, which
clearances we achieve.
makes it unsuitable for determining the impact of citrate
We did not monitor solute clearance rates routinely.
anticoagulation on survival in comparison with otherRather, we monitored the ultrafiltration rate hourly, and
methods of anticoagulation.clotting was suspected when the ultrafiltration rate was
In most respects, the performance of our system ispersistently low. It is well known that ultrafiltration rates
similar to that described by Mehta et al. However, ourfall with a longer duration of membrane use, possibly
system is considerably less complex. First, only a singlebecause of fiber clotting or because of an intrinsic prop-
replacement solution is employed without the use oferty of the membrane [27, 28]. However, studies have
dialysate. In contrast, the technique used by Mehta etshown that sieving coefficients are preserved up to a
al requires separate citrate and saline infusions as wellmean of 43 hours during hemofiltration (abstract; Golper
as a hypotonic, bicarbonate free dialysate. Second, theiret al, J Am Soc Nephrol 3:367, 1992). Thus, as long
technique requires close monitoring for metabolic alka-as ultrafiltration is maintained, clearance rates are also
losis and hypernatremia and treatment of these compli-maintained.
cations when they occur. These complications are notNo hemorrhagic episodes occurred during citrate anti-
associated with our system.coagulation in this high-risk population, which confirms
Currently, the main drawback of citrate-CRRT is theprevious reports on the safety of regional citrate antico-
cost of customized production of the citrate solution.agulation in CRRT (abstract; Mehta et al, J Am Soc
With advances in CRRT equipment and standardizationNephrol 4:368, 1993) [11]. No effect on coagulation pa-
of protocols, we believe that the demand for citrate solu-rameters was observed. In contrast, three of our patients
tions will grow and will soon be enough to attract manu-had developed severe bleeding complications during an-
facturers.ticoagulation with heparin. Furthermore, one patient had
We conclude that our simplified technique of regionaldeveloped heparin-induced thrombocytopenia.
citrate anticoagulation with CVVH is practical and effec-Evidence of citrate toxicity occurred in two of our
tive and can be used safely in critically ill patients withpatients. Both patients had severe lactic acidosis, one
from meningococcal sepsis and the other because of liver a high risk of bleeding.
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